Introduction. Adenosine is a metabolite that is produced in response to metabolic stress and cell injury, and acts through high-affinity A1 or A2A, and low-affinity A2B or A3 receptors. Adenosine suppresses immune responses through the A2AR. This study investigated the expression of A2A receptors in peripheral blood mononuclear cells (PBMCs) of patients with mild cognitive impairment (MCI), Alzheimer's disease (AD) and controls in order to verify if it may help distinguish different forms of cognitive decline. Methods. We analysed A 2A mRNA by real-time PCR and protein levels by westernblot in 41 subjects with AD, 10 with amnestic MCI (a-MCI), 49 with multiple impaired cognitive domains MCI (mcd-MCI) and 46 controls. Results. There was a significant linear increase in A2AR mRNA levels, from mcd-MCI (1.4 ± 0.1) to a-MCI patients (4 ± 1), with intermediate levels being found in controls (2 ± 0.2) and AD patients (2.5 ± 0.2). Similarly, there was a significant increase in A2AR density from mcd-MCI (0.4 ± 0.05) to a-MCI patients (0.7 ± 0.2), with intermediate levels being found in AD patients (0.5 ± 0.06) and controls (0.6 ± 0.05) (Fig. 1). In both analyses the difference between AD patients and controls was not statistically significant. Discussion. These data, which need to be confirmed in a larger number of patients, suggest that the expression of A2AR in PBMCs may be a valuable means of differentiating a-MCI and mcd-MCI.
|Translated title of the contribution||Adenosine A2A receptor expression in peripheral blood mononuclear cells of patients with mild cognitive impairment|
|Number of pages||7|
|Journal||Giornale di Gerontologia|
|Publication status||Published - Aug 2010|
ASJC Scopus subject areas
- Geriatrics and Gerontology